GLP-2 Analog global drug patents, pharmaceutical manufacturers and generics

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	GATTEX KIT	teduglutide	POWDER;SUBCUTANEOUS	203441-001	Dec 21, 2012		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y	⤷ Start Trial
Takeda Pharms Usa	GATTEX KIT	teduglutide	POWDER;SUBCUTANEOUS	203441-001	Dec 21, 2012		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Takeda Pharms Usa	GATTEX KIT	teduglutide	POWDER;SUBCUTANEOUS	203441-001	Dec 21, 2012		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: June 19, 2026

Executive summary: GLP-2 analogs are a small, defensible niche in inflammatory bowel disease, short bowel syndrome, and GI repair. Most category value is concentrated in teduglutide (GATTEX, Takeda). The patent estate for teduglutide drives near- to mid-term exclusivity and sets the practical bottleneck for entrants: process, formulation, and use patents typically outlast composition-of-matter in late lifecycle, and at least one “blocker” patent class has been litigated or used in settlement leverage. Other GLP-2 analogs (e.g., apraglutide, glepaglutide, and newer pipeline candidates) are earlier in development and face a different risk profile dominated by trial evidence, regulatory pathway, and smaller patent stacks. This makes the investment and licensing map less about broad “class exclusivity” and more about product-specific patent expiry sequencing, Orange Book or equivalent listings, and Paragraph IV readiness for teduglutide where the commercial base is largest.

Which GLP-2 analog drugs have market traction and where is the revenue concentrated?

Featured snippet answer: Teduglutide (GATTEX, Takeda) is the dominant GLP-2 analog with the largest commercial footprint; most other GLP-2 analogs remain limited by clinical positioning, slower reimbursement uptake, or ongoing development.

Teduglutide (GATTEX): current positioning and market drivers

Primary indication footprint

Short bowel syndrome with intestinal failure (adult and pediatric expansion in multiple geographies depending on label updates).
Reimbursement and payer criteria are key demand drivers, often linked to parenteral support reduction metrics.

Market dynamics

Uptake is constrained by:
- Injections and long-term treatment adherence.
- Clinical and payer thresholds (e.g., parenteral nutrition dependence).
- Safety monitoring requirements.
Competitive pressure is typically “within class” but entry timing matters because GLP-2 biology creates allowance for differentiated dosing, injection frequency, and patient subgroups.

Other GLP-2 analogs: why they have not displaced teduglutide

Examples (development or limited adoption)

Apraglutide (investigated in GI disorders; historical trial programs have not produced the same commercial scale as teduglutide).
Glepaglutide (development history varies by region and sponsor; not achieving broad commercial dominance vs teduglutide).

Structural reasons for weaker commercial dominance

Lack of a fully differentiated clinical edge strong enough to overcome:
- Established reimbursement and switching friction.
- Long-term safety and real-world evidence requirements.
- Mature manufacturing and distribution of the incumbent.

What patents protect teduglutide (GATTEX) and how many are in the estate?

Featured snippet answer: The teduglutide IP wall is product-specific and typically spans composition, peptide modifications and salts, manufacturing/process controls, and formulation/dosing device or stability claims. The practical “how many patents matter” count depends on jurisdiction and whether you include end-of-life formulation and method-of-use claims.

Estate structure that blocks generic or biosimilar-like entry

For GLP-2 analog small peptides, “generic-like” strategies usually hinge on proving equivalence in:

Active ingredient identity and any structural variants (unless claims cover the exact sequence).
Manufacturing parameters (process claims in some jurisdictions can be used as litigation leverage even if composition claims expire).
Formulation and stability (protecting excipients, concentration, lyophilization/solvent systems, or storage conditions).
Methods of use tied to indication and clinical biomarkers (e.g., intestinal absorption or parenteral nutrition reduction endpoints).

Patent categories that matter to freedom-to-operate

Composition of matter: sequence-specific peptide and variants (salts or hydrate forms).
Formulations: lyophilized cake composition, reconstitution buffer, stabilizers, and container-closure compatibility.
Methods of use: treatment regimens and patient selection criteria.
Manufacturing: process controls for peptide synthesis, purification, and impurity specifications.

Jurisdictional coverage

US is decisive for Orange Book-driven generic entry timing.
EU and UK coverage can extend commercial leverage via local enforcement and marketing authorization constraints.
In some markets, even if a composition claim ends, local formulation and method-of-use patents can maintain a de facto exclusivity barrier.

When does GATTEX (teduglutide) lose exclusivity and what is the patent expiration timeline?

Featured snippet answer: Exclusivity timing for teduglutide is governed by a combination of primary patent expiry plus later-expiring secondary patents (formulation and method-of-use), with US patent expiry sequence typically controlling “first legal generic launch” risk.

How to read the expiry sequence in practice

Step 1: primary composition-of-matter expiry establishes the earliest theoretical end of strong blocking coverage.
Step 2: later-expiring formulation/process patents can delay “workable” generic approvals or support injunction leverage.
Step 3: regulatory data exclusivity and pediatric exclusivity may extend exclusivity independent of patents.
Step 4: litigation stays or settlements can move real-world launch dates beyond statutory expiry.

Timeline mechanics that affect generic readiness

If later patents still block, generic filings may mature into:
- “Carve-out” strategies using non-infringing processes and formulations (high cost and complexity).
- Design-around of method-of-use claims (if label carve-outs are legally feasible).
- Settlement and delayed launch (common when the patent stack includes multiple enforceable claims).

What Paragraph IV challenges and patent litigation affect GLP-2 analog entry risk?

Featured snippet answer: The litigation and challenge pattern for GLP-2 analogs is product-specific, with teduglutide carrying the most credible US entry risk due to its market size and Orange Book visibility.

Why Paragraph IV matters more in teduglutide

A Paragraph IV challenge targets Orange Book-listed patents for an FDA-approved drug.
The presence of a dense patent list turns the generic strategy into a legal calendar problem, not only a chemistry problem.

Typical litigation pattern that shapes launch dates

Hatch-Waxman suit filed soon after FDA acceptance.
Injunction risk or settlement-based launch delay.
Post-settlement work on device/formulation/process to reduce further infringement exposure.

Litigation levers relevant to peptide drugs

Method-of-use patents create label design-around issues.
Formulation patents create manufacturing and stability constraints.
Process patents create production-line IP barriers even when the peptide sequence is identical.

What is the Orange Book status of teduglutide (GATTEX) and what does it imply for generic launch dates?

Featured snippet answer: Orange Book status determines which specific patents must be certified under Hatch-Waxman (including the most enforceable blocking patents). For teduglutide, the Orange Book listing is the primary input to “when a generic can legally start shipping.”

How Orange Book listings translate into an entry decision

Patent list length: more listed patents increases probability at least one blocks at time of launch.
Claim coverage breadth: broad claims on formulation and use reduce workarounds.
Expiration gaps: if the nearest expiration is short, the market often sees generic pressure followed by settlement or design-around filings.

What to track beyond listing

Labelling and indication scope that correspond to method-of-use patents.
Any museum piece patents with narrow claims are often less relevant to real entry.
Patent ownership changes can trigger enforcement strategy shifts.

What formulations are protected for GLP-2 analogs and how do formulation patents delay generics?

Featured snippet answer: Formulation and stability patents for injectable peptides can delay generic approval even after composition expiry because they can be independently infringed and often require non-infringing excipient systems and reconstitution characteristics.

Formulation patent hotspots for injectable GLP-2 analogs

Lyophilized powder composition and stabilizers.
Reconstitution solution components and pH targets.
Container-closure compatibility and adsorption controls.
Stability under temperature excursions and reconstitution-time limits.

Why formulation matters operationally

Generic sponsors typically must match:
- Impurity profiles.
- Dissolution behavior and reconstitution time.
- Shelf-life stability under real-world conditions.
Even if composition claims expire, formulation and process claims can still support an injunction strategy.

Do GLP-2 analogs face biosimilar-like risks or is the threat primarily small-molecule/generic?

Featured snippet answer: GLP-2 analogs are small peptides, so the credible threat class is “generic” or “follow-on peptide,” not biosimilar in the biologics pathway. Risk still includes formulation and process IP that can function like biologic-style product protection.

What changes for peptides vs biologics

Generic approval is still tied to FDA chemical generic frameworks for peptide drugs (depending on product classification).
The defense and infringement focus shifts from glycosylation heterogeneity to:
- Sequence identity
- Manufacturing process
- Purity and impurity thresholds
- Stability and formulation equivalence

How does teduglutide compare with other GLP-2 analogs on patent depth and defensibility?

Featured snippet answer: Teduglutide has the deepest commercial value concentration and typically the most enforceable IP stack; other GLP-2 analogs often have thinner IP visibility or are at earlier clinical stages with less concentrated payer-funded adoption.

Comparative dimensions used by licensors and challengers

Commercial base: revenue concentration predicts litigation appetite and sponsor enforcement intensity.
Patent list density: number of listed patents increases generic legal exposure.
Claim “blocking utility”: enforceability against a feasible design-around process.
Manufacturing complexity: strong process patents increase implementation risk.
Regulatory label scope: method-of-use claims increase label carve-out complexity.

Competitive landscape implication

Entrants in GLP-2 analogs often require either:
- A clinical differentiation strong enough to justify payer switching, or
- A legal pathway that clears the product’s Orange Book and enforcement obstacles.

Which companies are positioned to license or challenge GLP-2 analog IP?

Featured snippet answer: Takeda is the incumbent for teduglutide; challenger activity typically clusters around generic manufacturers that can operationalize peptide manufacture at scale and run credible Hatch-Waxman litigation strategies where Orange Book listings are dense.

Licensing playbook in the GLP-2 analog niche

Incumbents offer cross-licenses or delayed launches when:
- Patent infringement risk is high.
- Entrant manufacturing capabilities are credible.
- Market expansion is expected with label expansion or new subpopulations.

Why litigation readiness is a gate

For peptide drugs, legal and manufacturing capabilities must align. Even strong legal strategies fail if the manufacturing process cannot deliver matching impurity and stability profiles.

What generic entry risks exist for teduglutide under different launch scenarios?

Featured snippet answer: The key entry risks are delayed launch due to settlement or injunction, and potential redesign requirement for formulation/process to avoid later-expiring patents.

Scenario map

Early composition expiry clearance
- Risk: late-formulation or method-of-use patents still block.
- Outcome: carve-outs, non-infringing formulations, or settlement.
Settlement-driven “at-risk but delayed” launch
- Risk: limited competition horizon, margin compression.
- Outcome: generic launches at agreed date with narrowed label.
Design-around attempt
- Risk: manufacturing and stability equivalence failures.
- Outcome: regulatory or infringement disputes.
Injunction scenario
- Risk: revenue stoppage and sunk costs.
- Outcome: continued market exclusivity or resettlement.

What manufacturing and IP barriers could block follow-on GLP-2 analog products?

Featured snippet answer: For GLP-2 analog injectables, the main barriers are process patents, impurity-spec protected ranges, and formulation stability requirements linked to device and reconstitution.

IP-relevant manufacturing constraints

Synthetic route steps that are claimed.
Purification and chromatography parameters tied to impurity profiles.
Endotoxin control and residual solvent or peptide-related impurity specifications.
Stability-critical formulation parameters.

Operational risk to entrants

Even with equivalent peptide sequence, deviations can trigger:
- QC release failures.
- Stability failures.
- Patent infringement if claims cover process equivalents.

How do FDA regulatory status and exclusivity interact with the patent landscape for GLP-2 analogs?

Featured snippet answer: FDA exclusivity (data and, where applicable, pediatric or other statutory exclusivities) can extend market protection beyond patent expiry, while label timing can interact with method-of-use patents.

Regulatory levers that affect entry

Litigation timing under Hatch-Waxman affects when FDA can approve and when the sponsor can ship.
For method-of-use patents, label scope can determine infringement exposure.
Pediatric exclusivity can shift launch calendars even when the patent stack is near expiry.

Key takeaways

Teduglutide (GATTEX) drives the GLP-2 analog patent and market story. The category does not have a broadly shared exclusivity wall; protection is product-specific.
The decisive barriers are late-expiring formulation/process and method-of-use patents, not only primary composition claims.
Orange Book listings define the practical generic launch calendar. For teduglutide, patent list density and claim blocking utility are the main determinants of whether entry is feasible without settlement or design-around.
Entry risk is primarily Hatch-Waxman litigation driven. Settlement and label carve-out requirements are common downstream outcomes of a dense patent estate.
Manufacturing equivalence is an IP barrier. Process and impurity/stability protection can block “generic-like” follow-on products even when the sequence is the same.

FAQs

1) What patent types most often extend exclusivity for injectable GLP-2 analogs after composition expiry?
Formulation/stability, process manufacturing, and method-of-use claims commonly extend practical exclusivity.

2) How does a label carve-out strategy reduce infringement risk for GLP-2 analog method-of-use patents?
By narrowing the indication or patient population so the generic label does not practice the claimed method.

3) What drives settlement likelihood in teduglutide Hatch-Waxman disputes?
Patent stack density, injunction risk, and the sponsor’s ability to execute a non-infringing manufacturing and formulation plan.

4) Are GLP-2 analog follow-ons regulated like biosimilars or like generics?
GLP-2 analog peptide products are typically addressed through generic/follow-on pathways, with product protection centered on manufacturing and formulation rather than biologic structural heterogeneity.

5) What is the most important dataset to model generic launch timing for teduglutide?
Orange Book patent expiration and certification history, overlaid with litigation and settlement dates that affect shipping.

References

FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
FDA. “Hatch-Waxman Drug Patent Certifications (Paragraph IV).” U.S. Food and Drug Administration.
FDA. “Drug Products and Biological Products: Patent and Exclusivity Information.” U.S. Food and Drug Administration.